Status:
UNKNOWN
the Efficacy and Safety of Indobufen and Low-dose Aspirin in Different Regimens of Antiplatelet Therapy
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Conditions:
Coronary Atherosclerosis
Eligibility:
All Genders
18-75 years
Phase:
PHASE4
Brief Summary
A total of 210 coronary atherosclerosis patients without indications for stent implantation are included. The baseline values of platelet aggregation rate, plasmaThromboxaneB2 and urinary 11-dh Thromb...
Detailed Description
A total of 210 coronary atherosclerosis patients without indications for stent implantation are included. Exclusion criteria：Aspirin resistance, uncontrolled hypertension (\> 160 / 100mmHg),hemoglobin...
Eligibility Criteria
Inclusion
- Clinical diagnosis of coronary atherosclerosis without indications for stent implantation .
- Patient aged \>18 years and ≤75years. Must be able to swallow tablets
Exclusion
- Aspirin resistance; uncontrolled hypertension (\> 160 / 100mmHg); hemoglobin \<100g / L; hemorrhagic disease or bleeding tendency history; taking other non-steroidal drugs; severe liver disease history; malignant neoplasms; active gastric mucosa bleeding; PCI history; coronary artery bypass surgery; cardiac function grade Ⅳ.
Key Trial Info
Start Date :
August 20 2017
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
August 10 2018
Estimated Enrollment :
210 Patients enrolled
Trial Details
Trial ID
NCT03230851
Start Date
August 20 2017
End Date
August 10 2018
Last Update
July 31 2017
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
First Affiliated Hospital of Nanjing Medical University
Nanjing, Jiangsu, China, 210029